ReviewAnnals of translational medicine2016
The dual role of complement in cancer and its implication in anti-tumor therapy.
Review in Annals of translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 52 citations in OpenAlex.
- Overexpression of key complement regulators in glioblastoma.PloS one · 2026Article
- Variations in Circulating Tumor Microenvironment-Associated Proteins in Non-Muscle Invasive Bladder Cancer Induced by Mitomycin C Treatment.International journal of molecular sciences · 2025Article
- The decay-accelerating factor (CD55) in acute leukemia patients and its query implication in cancer pathogenesis.Journal of the Egyptian National Cancer Institute · 2025Article
- SERPING1 Reduces Cell Migration via ERK-MMP2-MMP-9 Cascade in Sorafenib- Resistant Hepatocellular Carcinoma.Environmental toxicology · 2025Article
- C1s targeting antibodies inhibit the growth of cutaneous squamous carcinoma cells.Scientific reports · 2024Article
- The Anti-Cancer Activity of the Naturally Occurring Dipeptide Carnosine: Potential for Breast Cancer.Cells · 2023Review
- Combined anti-C1-INH and radiotherapy against glioblastoma.BMC cancer · 2023Article
- Innate Immunity: A Balance between Disease and Adaption to Stress.Biomolecules · 2022Review
- Review
- Anti-Cancer Effects of Carnosine-A Dipeptide Molecule.Molecules (Basel, Switzerland) · 2021Article
- Review
- Reduced expression of innate immunity-related genes in lymph node metastases of luminal breast cancer patients.Scientific reports · 2021Article
- The role of complement in the tumor microenvironment.Faculty reviews · 2021Review
- Sulfated polymannuroguluronate TGC161 ameliorates leukopenia by inhibiting CD4Carbohydrate polymers · 2020Article
- Anti gC1qR/p32/HABP1 Antibody Therapy Decreases Tumor Growth in an Orthotopic Murine Xenotransplant Model of Triple Negative Breast Cancer.Antibodies (Basel, Switzerland) · 2020Article
- Deciphering the Intricate Roles of Radiation Therapy and Complement Activation in Cancer.International journal of radiation oncology, biology, physics · 2020Review
- Tumour-cell-derived complement components C1r and C1s promote growth of cutaneous squamous cell carcinoma.The British journal of dermatology · 2020Article
- gC1qR/HABP1/p32 Is a Potential New Therapeutic Target Against Mesothelioma.Frontiers in oncology · 2020Article
- Inflammaging and Complement System: A Link Between Acute Kidney Injury and Chronic Graft Damage.Frontiers in immunology · 2020Review
- Therapeutic Lessons to be Learned From the Role of Complement Regulators as Double-Edged Sword in Health and Disease.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic inflammation has been linked to the initiation of carcinogenesis, as well as the advancement of established tumors. The polarization of the tumor inflammatory microenvironment can contribute to either the control, or the progression of the disease. The emerging participation of members of the complement cascade in several hallmarks of cancer, renders it a potential target for anti-tumor treatment. Moreover, the presence of complement regulatory proteins (CRPs) in most types of tumor cells is known to impede anti-tumor therapies. This review focuses on our current knowledge of complement's potential involvement in shaping the inflammatory tumor microenvironment and its role on the regulation of angiogenesis and hypoxia. Furthermore, we discuss approaches using complement-based therapies as an adjuvant in tumor immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.